Brain perfusion imaging with voxel-based analysis in secondary progressive multiple sclerosis patients with a moderate to severe stage of disease: a boon for the workforce. | Canada Hyperbarics Skip to main content
Retrospective Study BMC neurology 2016

Brain perfusion imaging with voxel-based analysis in secondary progressive multiple sclerosis patients with a moderate to severe stage of disease: a boon for the workforce.

Taghizadeh Asl M, Nemati R, Chabi N, Salimipour H, Nabipour I, Assadi M — BMC neurology, 2016

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers retrospectively evaluated cerebral perfusion in 25 secondary progressive multiple sclerosis patients, comparing brain perfusion before and after hyperbaric oxygen therapy in a subset of 16 patients.

What They Found

Of 25 secondary progressive multiple sclerosis patients, 23 (92%) showed abnormal brain perfusion. The study found a significant association between the severity of perfusion impairment and both disease duration and EDSS scores (P < 0.05). Additionally, there was a significant improvement in brain perfusion scans following hyperbaric oxygen therapy (P < 0.05).

What This Means for Canadian Patients

This study suggests that brain perfusion imaging could be a valuable tool for assessing disease severity and monitoring potential treatment effects in Canadian patients with secondary progressive multiple sclerosis. While hyperbaric oxygen therapy showed improved perfusion, further research is needed to determine its practical clinical benefits for patients.

Canadian Relevance

This study has no direct Canadian connection.

Study Limitations

Key limitations include the retrospective design and the small sample size of only 25 patients, which limits the generalizability of the findings.

Was this summary helpful?

Study Details

Study Type Retrospective Study
Category Neurological
Source Pubmed
PubMed ID 27229156
Year Published 2016
Journal BMC neurology
MeSH Terms Adult; Cysteine; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuroimaging; Organotechnetium Compounds; Perfusion Imaging; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon

Cite This Study

Share
Discuss with a qualified healthcare professional. Then: Review Coverage Guide View Recognised Conditions

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.